These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9017629)

  • 1. Acute renal failure associated with carcinoid crisis.
    Parry RG; Glover S; Dudley CR
    Nephrol Dial Transplant; 1996 Dec; 11(12):2489-90. PubMed ID: 9017629
    [No Abstract]   [Full Text] [Related]  

  • 2. Regression of sclerodermatous skin lesions in a patient with carcinoid syndrome treated by octreotide.
    Pavlovic M; Saiag P; Lotz JP; Marinho E; Clerici T; Izrael V
    Arch Dermatol; 1995 Oct; 131(10):1207-9. PubMed ID: 7574845
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of carcinoid syndrome with ocreotide (SMS-201-995)].
    Rodríguez-García JL; Arechaga S; Fraile G; Serrano M
    Rev Clin Esp; 1992 Jul; 191(3):168. PubMed ID: 1380173
    [No Abstract]   [Full Text] [Related]  

  • 4. Anesthetic considerations and management of a patient with unsuspected carcinoid crisis during hepatic tumor resection.
    Choi CK
    Middle East J Anaesthesiol; 2014 Jun; 22(5):515-8. PubMed ID: 25137869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours.
    Kinney MA; Warner ME; Nagorney DM; Rubin J; Schroeder DR; Maxson PM; Warner MA
    Br J Anaesth; 2001 Sep; 87(3):447-52. PubMed ID: 11517130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Update on the anesthetic management of patients with malignant carcinoid syndrome].
    Rodríguez-Cosmen C; Trillo Urrutia L; Pacreu Terradas S; Comps Vicente O; Escolano Villén F
    Rev Esp Anestesiol Reanim; 2005 May; 52(5):291-4. PubMed ID: 15968907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.
    Kulke MH; O'Dorisio T; Phan A; Bergsland E; Law L; Banks P; Freiman J; Frazier K; Jackson J; Yao JC; Kvols L; Lapuerta P; Zambrowicz B; Fleming D; Sands A
    Endocr Relat Cancer; 2014 Oct; 21(5):705-14. PubMed ID: 25012985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
    Kulke MH; Hörsch D; Caplin ME; Anthony LB; Bergsland E; Öberg K; Welin S; Warner RR; Lombard-Bohas C; Kunz PL; Grande E; Valle JW; Fleming D; Lapuerta P; Banks P; Jackson S; Zambrowicz B; Sands AT; Pavel M
    J Clin Oncol; 2017 Jan; 35(1):14-23. PubMed ID: 27918724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR inhibitor therapy for patients with carcinoid.
    Rindi G; Caplin M
    Lancet; 2011 Dec; 378(9808):1978-1980. PubMed ID: 22119494
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis.
    Ammann M; Kinney MAO; Gudmundsdottir H; Santol J; Thiels CA; Warner SG; Truty MJ; Kendrick ML; Smoot RL; Anderson AL; Halfdanarson TR; Nagorney DM; Starlinger PP
    Ann Surg Oncol; 2024 Jun; 31(6):3976-3977. PubMed ID: 38619707
    [No Abstract]   [Full Text] [Related]  

  • 11. Case report--carcinoid syndrome: two case reports from reserve unit.
    Smith DF
    J R Nav Med Serv; 2011; 97(2):66-71. PubMed ID: 22013639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review.
    Seymour N; Sawh SC
    Can J Anaesth; 2013 May; 60(5):492-9. PubMed ID: 23328959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter to the Editor Concerning "Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis" by Ammann, Markus et al.
    Pommier R
    Ann Surg Oncol; 2024 Aug; 31(8):5130-5131. PubMed ID: 38844630
    [No Abstract]   [Full Text] [Related]  

  • 14. Response to increasing doses of octreotide in a patient with carcinoid syndrome.
    Ajani JA; Chesnut JR
    Eur J Cancer; 1993; 29A(16):2332-3. PubMed ID: 7509166
    [No Abstract]   [Full Text] [Related]  

  • 15. [A prolonged-action somatostatin analog and carcinoid syndrome].
    Chayvialle JA
    Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudocarcinoid syndrome associated with hypogonadism and response to testosterone therapy.
    Shakir KM; Jasser MZ; Yoshihashi AK; Drake AJ; Eisold JF
    Mayo Clin Proc; 1996 Dec; 71(12):1145-9. PubMed ID: 8945484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment with octreotide (SMS 201-995) in a case of intestinal carcinoid tumor].
    Goñi F; Oleaga A; Goñi MJ; Monreal M; Yoldi A; González A; Llorente I; Moncada E
    Rev Clin Esp; 1991 Nov; 189(7):331-4. PubMed ID: 1722585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
    Janson ET; Oberg K
    Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome.
    Oberg K; Norheim I; Theodorsson E; Ahlman H; Lundqvist G; Wide L
    J Clin Endocrinol Metab; 1989 Apr; 68(4):796-800. PubMed ID: 2466045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Carcinoid syndrome. II. Clinical manifestations, diagnosis, prognosis and treatment].
    Díaz Recasens J; Ruíz Palomo F; Pérez Corral F; Rapado A
    Rev Clin Esp; 1974 Jan; 132(2):91-8. PubMed ID: 4840233
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.